Trends in Opioid Agonist Treatment for Opioid Dependence During Pregnancy: A Population‐Based Study in New South Wales 2005–2021

Three in four people in the cohort received OAT during pregnancy, with no statistically significant change in annual prevalence over the 2005-2021 period. Given prior evidence indicating higher rates of treatment discontinuation with buprenorphine versus methadone, the increased buprenorphine use during pregnancy highlights the need for targeted strategies to support treatment retention.